Chi-Fu Jeffrey Yang, MD, Derek Y. Chan, BSE, Paul J

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer Jeffrey L. Port, MD, Bhupesh Parashar,

Thomas J. Birdas, MD, Richard P. M

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Postoperative Atrial Fibrillation Prophylaxis After Lung Surgery: Systematic Review and Meta-Analysis Lars Peter Riber, MD, PhD, Torben Bjerregaard Larsen,

Trevor Williams, MD, MPH, Brian C

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer Paul J. Speicher, MD, Zachary W. Fitch,

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Loretta Erhunmwunsee, MD, Brian C

How I Teach a Thoracoscopic Lobectomy

Mark F. Berry, MD, Nestor R. Villamizar-Ortiz, MD, Betty C

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Mohamed K. Kamel, MD, Mohamed Rahouma, MD, Benjamin Lee, MD, Sebron W

Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Population- Based Analysis Babatunde A. Yerokun, MD, Zhifei Sun, MD, Chi-Fu Jeffrey.

A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer Brian C. Gulack, MD, Chi-Fu Jeffrey Yang,

Andrea S. Wolf, MD, MPH, Scott J

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Trevor Williams, MD, MPH, Brian C

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Andrea S. Wolf, MD, William G. Richards, PhD, Michael T

Surgical Considerations for the Management and Resection of Esophageal Gastrointestinal Stromal Tumors Matthew G. Blum, MD, Karl Y. Bilimoria, MD, Jeffrey.

Kevin L. Anderson, MHSc, Michael S. Mulvihill, MD, Paul J

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Jaimin R. Trivedi, MD, MPH, Allen Cheng, MD, Michele Gallo, MD, Erin M

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? Samuel Kim, MD, David A. Bull, MD, Linda Garland, MD,

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Risk Factors for Atrial Fibrillation After Lung Cancer Surgery: Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database Mark Onaitis,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Patient Preferences in Treatment Choices for Early-Stage Lung Cancer

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Asvin M. Ganapathi, MD, Paul J. Speicher, MD, Anthony W

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Single Versus Double Lung Retransplantation Does Not Affect Survival Based on Previous Transplant Type Erin M. Schumer, MD, MPH, Jonathan D. Rice, MD,

Does the Approach Matter

Specialty Training and Mortality After Esophageal Cancer Resection

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Lobectomy for Lung Cancer at Veterans Administration Medical Center Versus Academic Medical Center Travis Geraci, MD, Vanessa Baratta, MD, John Young,

Mark I. Block, MD The Annals of Thoracic Surgery

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I.

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Presentation transcript:

Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer Chi-Fu Jeffrey Yang, MD, Derek Y. Chan, BSE, Paul J. Speicher, MD, Brian C. Gulack, MD, Betty C. Tong, MD, Matthew G. Hartwig, MD, Christopher R. Kelsey, MD, Thomas A. D’Amico, MD, Mark F. Berry, MD, David H. Harpole, MD The Annals of Thoracic Surgery Volume 103, Issue 6, Pages 1767-1772 (June 2017) DOI: 10.1016/j.athoracsur.2017.01.043 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Consolidated Standards of Reporting Trials (CONSORT) diagram showing schema of study subject selection (clinical T1–3 N1 M0 patients). (RT = radiation; SCLC = small cell lung cancer.) The Annals of Thoracic Surgery 2017 103, 1767-1772DOI: (10.1016/j.athoracsur.2017.01.043) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Overall survival of cT1–3 N1 M0 small cell lung cancer (SCLC) patients, stratified by surgery versus concurrent chemoradiation. (CI = confidence interval; RT = radiation.) The Annals of Thoracic Surgery 2017 103, 1767-1772DOI: (10.1016/j.athoracsur.2017.01.043) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Overall survival of cT1–3 N1 M0 small cell lung cancer (SCLC) patients, stratified by surgery versus concurrent chemoradiation: propensity score-matched analysis. (CI = confidence interval; RT = radiation.) The Annals of Thoracic Surgery 2017 103, 1767-1772DOI: (10.1016/j.athoracsur.2017.01.043) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 (A) Overall survival of cT1–3 N1 M0 small cell lung cancer (SCLC) patients who underwent wedge resection versus lobectomy. (B) Overall survival of cT1–3 N1 M0 SCLC patients who underwent wedge resection or lobectomy and did not have positive margins. (CI = confidence interval.) The Annals of Thoracic Surgery 2017 103, 1767-1772DOI: (10.1016/j.athoracsur.2017.01.043) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 5 Overall survival of cT1–3 N1 M0 small cell lung cancer (SCLC) patients with no comorbidities, stratified by surgery versus concurrent chemoradiation. (CI = confidence interval; RT = radiation.) The Annals of Thoracic Surgery 2017 103, 1767-1772DOI: (10.1016/j.athoracsur.2017.01.043) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions